Abstract
Paclitaxel and docetaxel are two key molecules in the treatment of a variety of cancers with major impact in the treatment of breast, lung and ovarian cancers. A number of taxoids have then been synthesized in an effort to improve some of the features of the existing drugs. Although the literature is still scant of preclinical data due to the highly competitive field, several compounds are already in clinical trials. Most of these will be reviewed and have, either improved water solubility or reduced cross-resistance with marketed taxoids or reduced interaction with P-glycoprotein. In addition, the reduced recognition of several compounds by multi-drug-resistance-related transport systems has yielded some orally bioavailable compounds with marked in vivo antitumor activity. It is likely that these additional properties should lead to an expanded spectrum of clinical activity compared to that of clinically available taxoids.
Keywords: Taxoids, Cytotoxicity, Taxus, TXD258, RPR 109881A, BMS 185660, BMS 188797, BMS 184476
Current Pharmaceutical Design
Title: Preclinical Evaluation of New Taxoids
Volume: 7 Issue: 13
Author(s): M. -C. Bissery
Affiliation:
Keywords: Taxoids, Cytotoxicity, Taxus, TXD258, RPR 109881A, BMS 185660, BMS 188797, BMS 184476
Abstract: Paclitaxel and docetaxel are two key molecules in the treatment of a variety of cancers with major impact in the treatment of breast, lung and ovarian cancers. A number of taxoids have then been synthesized in an effort to improve some of the features of the existing drugs. Although the literature is still scant of preclinical data due to the highly competitive field, several compounds are already in clinical trials. Most of these will be reviewed and have, either improved water solubility or reduced cross-resistance with marketed taxoids or reduced interaction with P-glycoprotein. In addition, the reduced recognition of several compounds by multi-drug-resistance-related transport systems has yielded some orally bioavailable compounds with marked in vivo antitumor activity. It is likely that these additional properties should lead to an expanded spectrum of clinical activity compared to that of clinically available taxoids.
Export Options
About this article
Cite this article as:
Bissery -C. M., Preclinical Evaluation of New Taxoids, Current Pharmaceutical Design 2001; 7 (13) . https://dx.doi.org/10.2174/1381612013397465
DOI https://dx.doi.org/10.2174/1381612013397465 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Phenotypic Screening for Pharmaceuticals Using Tissue Constructs
Current Pharmaceutical Biotechnology Editorial (Thematic Issue: Perspectives on Strategies for Overcoming Cancer Therapy Resistance)
Current Protein & Peptide Science Molecular Evaluation of PROGINS Mutation in Progesterone Receptor Gene and Determination of its Frequency, Distribution Pattern and Association with Breast Cancer Susceptibility in Saudi Arabia
Endocrine, Metabolic & Immune Disorders - Drug Targets DTCM-glutarimide Delays Growth and Radiosensitizes Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry HSP90 Inhibitors: Multi-Targeted Antitumor Effects and Novel Combinatorial Therapeutic Approaches in Cancer Therapy
Current Medicinal Chemistry Insect Peptides – Perspectives in Human Diseases Treatment
Current Medicinal Chemistry Old Wine in a New Bottle: The Warburg Effect and Anticancer Mechanisms of Resveratrol
Current Pharmaceutical Design Current Insights into the Role of HIF-1 in Cutaneous Wound Healing
Current Molecular Medicine Activation of Sphingosine Kinase-1 in Cancer: Implications for Therapeutic Targeting
Current Molecular Pharmacology Glutamine, Glucose and other Fuels for Cancer
Current Pharmaceutical Design Study of Parasitic Infections, Cancer, and other Diseases with Mass-Spectrometry and Quantitative Proteome-Disease Relationships
Current Proteomics NIPAM/PEG/ MoS2 Nanosheets for Dual Triggered Doxorubicin Release and Combined Chemo-photothermal Cancer Therapy
Current Drug Delivery Targeted Drug Delivery in Brain Tumors-nanochemistry Applications and Advances
Current Topics in Medicinal Chemistry Small Molecular Inhibitors Targeting Chromatin Regulating Proteins for Cancer
Current Protein & Peptide Science Status of Non-Classical Mononuclear Platinum Anticancer Drug Development
Mini-Reviews in Medicinal Chemistry Verbascoside Attenuates Rac-1 and HIF-1α Signaling Cascade in Colorectal Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Recent Advances and Strategies in Tumor Vasculature Targeted Nano-Drug Delivery Systems
Current Pharmaceutical Design Clinical Pharmacology of Trastuzumab
Current Clinical Pharmacology Rationale for an Intraperitoneal Gemcitabine Chemotherapy Treatment for Patients with Resected Pancreatic Cancer
Recent Patents on Anti-Cancer Drug Discovery Heterocyclic Scaffolds: Centrality in Anticancer Drug Development
Current Drug Targets